Customer and Supplier Concentration

12 Months Ended

Dec. 31, 2015

7. Customer and Supplier Concentration

Customer Concentrations

Three large wholesale drug distributors, AmerisourceBergen Corporation, or AmerisourceBergen, Cardinal Health, Inc. or Cardinal, and McKesson Corporation, or McKesson, are all distributors of the Company’s products, as well as suppliers of a broad range of health care products. Allergan plc. has exclusive marketing rights of the Company’s enoxaparin product to the U.S. retail pharmacy market. MannKind Corporation began buying RHI API from the Company in December 2014. The Company considers these five customers to be its major customers, as each individually and these customers collectively, represented a significant percentage of the Company’s net revenue for the years ended December 31, 2015, 2014, and 2013, and accounts receivable as of December 31, 2015 and 2014. The following table provides accounts receivable and net revenues information for these major customers:


	% of Total Accounts				% of Net
	Receivable				Revenue
	December 31,		December 31,		Year Ended December 31,
	2015		2014		2015		2014		2013
Allergan plc(1)	12	%	18	%	21	%	30	%	35	%
AmerisourceBergen	12	%	5	%	17	%	15	%	15	%
Cardinal Health	20	%	15	%	17	%	14	%	13	%
MannKind Corporation	13	%	21	%	8	%	2	%	—
McKesson	21	%	13	%	22	%	22	%	26	%

⁽¹⁾

In June 2015, Actavis plc adopted Allergan plc as its new global name.

Supplier Concentrations

The Company depends on suppliers for raw materials, active pharmaceutical ingredients, and other components that are subject to stringent U.S. Food and Drug Administration, or FDA, requirements. Some of these materials may only be available from one or a limited number of sources. Establishing additional or replacement suppliers for these materials may take a substantial period of time, as suppliers must be approved by the FDA. Furthermore, a significant portion of raw materials may only be available from foreign sources. If the Company is unable to secure, on a timely basis, sufficient quantities of the materials it depends on to manufacture and market its products, it could have a materially adverse effect on the Company’s business, financial condition, and results of operations.